Resistance To Anti-HER2 Therapy In Breast Cancer Patients May Be Delayed By Treatment Targeting PI3K

Patients with HER2-positive breast cancer being treated with anti-HER2 therapy may be able to prevent or delay resistance to the therapy with the addition of a phosphatidylinositol-3 kinase inhibitor to their treatment regimens. The data, published in Cancer Research, a journal of the American Association for Cancer Research, indicated that failure of the anti-HER2 antibody trastuzumab to block HER2 from activating the phosphatidylinositol-3 kinase (PI3K) signaling pathway can lead to resistance to treatment...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Breast Cancer Source Type: news